Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Dr. Samuel H. Mehr

Radiology | Nuclear Medicine
Oncology Hematology West, PC
8303 Dodge St, Suite 250, 
Omaha, NE 
Accepting New Patients
Offers Telehealth
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Oncology Hematology West, PC
8303 Dodge St, Suite 250, 
Omaha, NE 
OverviewInsuranceLocationsClinical Research

Overview

Samuel Mehr is a Radiologist and a Nuclear Medicine provider in Omaha, Nebraska. Dr. Mehr is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Small Lymphocytic Lymphoma (SLL), and Classical Hodgkin Lymphoma. Dr. Mehr is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Specialties
Radiology
Nuclear Medicine
Licenses
Nuclear Medicine in IA
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellmark
  • HMO
  • POS
View 4 Less Insurance Carriers -

Locations

ONCOLOGY HEMATOLOGY WEST, PC
8303 Dodge St, Suite 250, Omaha, NE 68114
Other Locations
ONCOLOGY HEMATOLOGY WEST, PC
17201 Wright St, Suite 200, Omaha, NE 68130
ONCOLOGY HEMATOLOGY WEST, PC
7500 Mercy Rd, Omaha, NE 68124

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3

1 Total Publications

Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.
Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.
Journal: Pancreas
Published: May 18, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehr's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 32 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile